Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Vascepa® Granted Priority Review Status from Health Canada New Drug Submission (NDS) for Vascepa in Canada Anticipated to Be Filed in April 2019 by HLS Therapeutics, Under Agreement with Amarin
BEDMINSTER, N.J., and DUBLIN, Ireland, March 29, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a pharmaceutical company focused on improving cardiovascular health, today announced that its licensee in Canada, HLS Therapeutics Inc. (TSX: HLS ), has received formal confirmation
View HTML
Toggle Summary Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study
BEDMINSTER, N.J. , and DUBLIN, Ireland , March 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that, as planned, it submitted a supplemental new drug application (sNDA) to the U.S.
View HTML
Toggle Summary New Updates to the American Diabetes Association’s® 2019 Standards of Medical Care in Diabetes Incorporate Findings from the REDUCE-IT™ Cardiovascular Outcomes Study
BEDMINSTER, N.J. , and DUBLIN, Ireland , March 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today confirmed that the American Diabetes Association® (ADA) issued important updates to the Standards of Medical
View HTML
Toggle Summary Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68th Annual Scientific Session
Anti-Oxidant Effects of Eicosapentaenoic Acid Data at Pharmacologic Concentrations Also Presented BEDMINSTER, N.J. , and DUBLIN, Ireland , March 19, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, in addition to its
View HTML
Toggle Summary Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Levels
BEDMINSTER, N.J. and DUBLIN, Ireland , March 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that real-world data reported by the U.S. Veteran’s Administration supports that patients with
View HTML
Toggle Summary Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa Usage Grow Over Time Amarin Schedules Webcast Discussion of Presented Data Today, March 18, 2019 at 4:00-5:00 pm CT BEDMINSTER, N.J.
View HTML
Toggle Summary High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease
BEDMINSTER, N.J. and DUBLIN, Ireland , March 16, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today the presentation of data and analysis which concluded that over nine million atherosclerotic
View HTML
Toggle Summary Amarin to Present at Cowen’s 39th Annual Health Care Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , March 05, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Important New Data on Vascepa® (Icosapent Ethyl) from the REDUCE-IT™ Trial to Be Presented Regarding Reduction in Total Ischemic Events
Multiple Scientific Presentations Scheduled for American College of Cardiology’s  68th Annual Scientific Session Amarin to Webcast Discussion of Presented Data March 18 , 4:00-5:00 pm Central Time BEDMINSTER, N.J. , and DUBLIN, Ireland , March 04, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc
View HTML
Toggle Summary Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations
Record Revenue of $229.2 Million and $ 77.3 Million for Full Year and Fourth Quarter 2018   REDUCE-IT™ sNDA Submission Remains on Schedule to be Filed Before the End of Q1 2019 Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J. , and DUBLIN, Ireland , Feb.
View HTML

Amarin Corporation